OA10151A - Method of administering azithromycin - Google Patents

Method of administering azithromycin Download PDF

Info

Publication number
OA10151A
OA10151A OA60654A OA60654A OA10151A OA 10151 A OA10151 A OA 10151A OA 60654 A OA60654 A OA 60654A OA 60654 A OA60654 A OA 60654A OA 10151 A OA10151 A OA 10151A
Authority
OA
OAPI
Prior art keywords
azithromycin
dosage form
food
exhibit
suspension
Prior art date
Application number
OA60654A
Other languages
English (en)
Inventor
William J Curatolo
George H Foulds
Hylar L Friedman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of OA10151A publication Critical patent/OA10151A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
OA60654A 1994-04-29 1995-04-28 Method of administering azithromycin OA10151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (1)

Publication Number Publication Date
OA10151A true OA10151A (en) 1996-12-18

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60654A OA10151A (en) 1994-04-29 1995-04-28 Method of administering azithromycin

Country Status (31)

Country Link
US (2) US5605889A (uk)
EP (1) EP0679400B1 (uk)
JP (3) JPH07300420A (uk)
KR (1) KR100354310B1 (uk)
CN (1) CN1088362C (uk)
AP (1) AP566A (uk)
AT (1) ATE183395T1 (uk)
AU (1) AU709328B2 (uk)
CA (1) CA2148071C (uk)
CO (1) CO4560547A1 (uk)
DE (1) DE69511451T2 (uk)
DK (1) DK0679400T3 (uk)
DZ (1) DZ1877A1 (uk)
ES (1) ES2136247T3 (uk)
FI (1) FI952060A (uk)
GR (1) GR3031290T3 (uk)
HU (1) HUT75244A (uk)
IL (1) IL113437A (uk)
LV (1) LV10918B (uk)
MA (1) MA23533A1 (uk)
NO (1) NO314386B1 (uk)
NZ (1) NZ548384A (uk)
OA (1) OA10151A (uk)
RU (1) RU2128998C1 (uk)
SI (1) SI0679400T1 (uk)
TN (1) TNSN95046A1 (uk)
TW (1) TW499311B (uk)
UA (1) UA34464C2 (uk)
UY (1) UY23935A1 (uk)
YU (1) YU49483B (uk)
ZA (1) ZA953439B (uk)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69524214T3 (de) * 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
ES2175073T3 (es) * 1995-02-08 2002-11-16 Yamanouchi Europ Bv Procedimiento de preparacion de formas para la administracion oral de antibioticos beta-lactamicos de rapida dispersabilidad en agua.
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
KR100575389B1 (ko) * 1997-12-22 2006-05-03 쉐링 코포레이션 경구 투여가능한 고체 리바비린 투여형 및 이의 제조 방법
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
EE05022B1 (et) * 1999-03-31 2008-06-16 Janssen Pharmaceutica N.V. Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
WO2002010144A1 (es) * 2000-07-25 2002-02-07 Laboratorio Silanes, S.A. De C.V. PROCESO PARA LA PREPARACION EN UN SOLO PASO DE 7,16-DIOXA-2-AZA-10-O-CLADINOSIL-12-O-DESOSAMINIL-4,5-DIHIDROXI-6-ETIL-3,5,9,11,13,15-HEXAMETILBICICLO[11.2.1]HEXADECA-1(2)-EN-8-ONA Y OBTENCION DE UNA FORMA NUEVA DE 9-DESOXO-9a-AZA-9a-METIL-9a-HOMOERITROMICINA A
CA2419873A1 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
WO2002036735A2 (en) * 2000-11-06 2002-05-10 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US7119076B2 (en) * 2000-11-15 2006-10-10 Masao Sugamata Preventives or remedies for endometriosis or uterine myoma
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1671979B1 (en) 2001-05-22 2008-08-13 Pfizer Products Inc. New Cristal Form of Azithromycin
CZ20033154A3 (en) * 2001-05-22 2004-04-14 Pfizer Products Inc. Crystal forms of azithromycin
SK1012004A3 (sk) * 2001-08-21 2005-04-01 Pfizer Products Inc. Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2003032922A2 (en) 2001-10-18 2003-04-24 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
PL371259A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Directly compressible formulations of azithromycin
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
EP1476191A2 (en) * 2002-01-16 2004-11-17 Pepgen Corporation Oral administration of interferon-tau
WO2003063838A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin
US20030175355A1 (en) * 2002-03-07 2003-09-18 Tobyn Michael John Fast melt multiparticulate formulations for oral delivery
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
WO2004074132A1 (en) * 2003-02-19 2004-09-02 Teva Pharmaceutical Industries Ltd. Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
AU2004238253B2 (en) * 2003-05-06 2011-01-27 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1648473B1 (en) * 2003-07-24 2009-01-28 PLIVA HRVATSKA d.o.o. Single dose fast dissolving azithromycin
AR045142A1 (es) * 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053651A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
AU2004216676B2 (en) * 2003-12-04 2011-06-16 Pfizer Products Inc. Azithromycin dosage forms with reduced side effects
CN1889933A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 由基于液体的工艺制备的阿奇霉素多颗粒剂型
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053655A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co IMPROVING THE IMMUNE RESPONSE
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
CN101111245A (zh) * 2005-01-27 2008-01-23 阿雷姆贝克有限公司 左乙拉西坦延长释放制剂
JP2008528583A (ja) * 2005-03-07 2008-07-31 テバ ファーマシューティカル インダストリーズ リミティド 経口懸濁用のアジスロマイシン粉末組成物
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
CN102048734B (zh) 2005-05-26 2013-11-20 大日本住友制药株式会社 药物组合物
US20080274178A1 (en) * 2005-08-10 2008-11-06 Shionogi & Co., Ltd. Orally Disintegrating Tablet
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
PL3061454T3 (pl) 2012-02-06 2021-09-20 Boehringer Ingelheim Animal Health USA Inc. Pasożytobójcze doustne kompozycje weterynaryjne obejmujące systemowo działające środki aktywne, sposoby i ich zastosowania
EP2821066B1 (en) 2012-02-28 2018-04-25 Seoul Pharma. Co. Ltd. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
EP3068227A4 (en) * 2013-11-11 2017-06-21 Forest Laboratories Holdings Limited Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
WO1989000576A1 (en) 1987-07-09 1989-01-26 Pfizer Inc. Azithromycin dihydrate
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0553353A1 (en) * 1990-10-15 1993-08-04 Taisho Pharmaceutical Co. Ltd 2'-modified erythromycin or derivative thereof
TW271400B (uk) * 1992-07-30 1996-03-01 Pfizer
EP0721324A1 (en) 1993-10-01 1996-07-17 The Procter & Gamble Company Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
DE69524214T3 (de) 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe

Also Published As

Publication number Publication date
IL113437A (en) 2001-04-30
DZ1877A1 (fr) 2002-02-17
FI952060A0 (fi) 1995-04-28
NO951630D0 (no) 1995-04-28
TNSN95046A1 (fr) 1996-02-06
MA23533A1 (fr) 1995-12-31
IL113437A0 (en) 1995-07-31
DE69511451T2 (de) 1999-12-09
AP9500728A0 (en) 1995-04-30
EP0679400B1 (en) 1999-08-18
US5605889A (en) 1997-02-25
CA2148071A1 (en) 1995-10-30
HUT75244A (en) 1997-05-28
NZ548384A (en) 2008-04-30
AP566A (en) 1996-11-22
SI0679400T1 (en) 1999-10-31
ES2136247T3 (es) 1999-11-16
AU709328B2 (en) 1999-08-26
YU49483B (sh) 2006-08-17
YU27195A (sh) 1999-03-04
DE69511451D1 (de) 1999-09-23
EP0679400A1 (en) 1995-11-02
JP2008231120A (ja) 2008-10-02
AU1771195A (en) 1995-11-09
TW499311B (en) 2002-08-21
FI952060A (fi) 1995-10-30
KR100354310B1 (ko) 2002-12-26
GR3031290T3 (en) 1999-12-31
LV10918A (lv) 1995-12-20
ZA953439B (en) 1996-10-28
HU9501206D0 (en) 1995-06-28
CN1088362C (zh) 2002-07-31
ATE183395T1 (de) 1999-09-15
NO314386B1 (no) 2003-03-17
RU95106639A (ru) 1997-01-20
CA2148071C (en) 2000-10-17
LV10918B (en) 1996-06-20
CO4560547A1 (es) 1998-02-10
USRE39149E1 (en) 2006-06-27
CN1114879A (zh) 1996-01-17
KR950028764A (ko) 1995-11-22
UA34464C2 (uk) 2001-03-15
NO951630L (no) 1995-10-30
RU2128998C1 (ru) 1999-04-20
JP2005015466A (ja) 2005-01-20
JPH07300420A (ja) 1995-11-14
UY23935A1 (es) 1995-09-12
DK0679400T3 (da) 1999-12-06

Similar Documents

Publication Publication Date Title
US5605889A (en) Method of administering azithromycin
FI90393B (fi) Menetelmä oraalisen, farmaseuttisen valmisteen valmistamiseksi, joka on pysyvä värin muuttumista vastaan
US4321253A (en) Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
US4587118A (en) Dry sustained release theophylline oral formulation
US4717569A (en) Unit dosage form of sparingly soluble medicaments
KR960011772B1 (ko) 개선된 디데옥시 퓨린 뉴클레오사이드 경구 투여 제제
EP2544660B1 (en) Rifaximin ready-to-use suspension
PT582396E (pt) Composicoes para mascarar o gosto amargo de agentes farmaceuticos
KR20020049004A (ko) 옥스카르바제핀을 포함하는 제약 조성물
JP2007532416A (ja) 液状の配合物を調合するための容器
CZ332598A3 (cs) Pevná dávková forma cisapridu
IE883583L (en) Spray dried ibuprofen
BRPI0820308B1 (pt) Composição farmacêutica compreendendo oxi-hidróxido de ferro em alta carga, seus usos e seus processos de preparação, e comprimido
BRPI0414860B1 (pt) uso de composição de fenofibrato em um medicamento para tratar hipertrigliceridemias, hipercolesterolemias ou hiperlipidemias ao mesmo tempo que reduzindo o efeito da alimentação sobre a biodisponibilidade de fenofibrato
AU744318B2 (en) Method of administering azithromycin
MXPA05000301A (es) Formas de dosificacion liquida de inhibidores de bomba de proton.
WO2004087108A1 (en) Taste-masking vehicle for coated oxazolidinone particles
EP0835654A1 (en) Glucomannan-containing orally administered pharmaceutical preparations with sustained effect
KR20000050265A (ko) 아지스로마이신 경구 투여 제형을 포함하는 치료용 패키지